Supplementary Data from Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations

Supplementary methods and figure legends. Figure S1 shows further characterization of Capan1 olaparib resistant cells and rucaparib resistant Capan1 cells. Figure S2 shows that drug efflux is unchanged in Capan1 olaparib resistant cells and truncated BRCA2 is overexpressed in rucaparib resistant Capan1 cells. Figure S3 shows that Capan1 olaparib resistant cells express truncated BRCA2 Figure S4 shows that Capan1 PARP inhibitor resistant cells form Rad51 and BRCA1 foci after irradiation. Figure S5 shows that BRCA2 knockdown sensitizes Capan1 olaparib resistant cells to olaparib. Figure S6 shows that BRCA2 peptide coverage and pinometostat-mediated reduction in H3K79Me in olaparib resistant Capan1 cells. Also DOT1L expression conveys poor prognosis in ovarian cancer and DOT1L knockdown reduced viability of an olaparib resistant ovarian cancer cell line.